CAR-T therapy is "not perfect"
One-time treatment can prevent disease progression or reverse disease progression, potentially alleviating the underlying causes of disease or even curing it. The efficacy of cell therapy has given hope to countless cancer patients, but with prices often in the millions, this drug is destined for only a few and is difficult for ordinary people to afford.
Even without the added risk of cancer, current CAR-T cell therapy is not a "perfect" cancer drug.
At present, the efficacy of CAR-T therapy is mainly demonstrated in hematologic malignancies, especially malignant lymphomas and multiple myeloma. Hindered by the tumor barrier, solid tumors have always been a hurdle for CAR-T therapy to overcome.
